A resolution designating July 15, 2026, as "Glioblastoma Awareness Day".

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 786 Agreed to Senate (ATS)]

<DOC>

119th CONGRESS
  2d Session
S. RES. 786

     Designating July 15, 2026, as ``Glioblastoma Awareness Day''.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             June 23, 2026

 Mr. Graham (for himself, Mr. Kelly, Mr. Barrasso, Mr. Scott of South
   Carolina, Mr. Van Hollen, Mr. Markey, Ms. Warren, Mr. Coons, Mr.
 Gallego, and Mrs. Shaheen) submitted the following resolution; which
                      was considered and agreed to

_______________________________________________________________________

                               RESOLUTION

     Designating July 15, 2026, as ``Glioblastoma Awareness Day''.

Whereas it is estimated that more than 13,000 individuals in the United States
        will be diagnosed with glioblastoma in 2026;
Whereas glioblastoma is--

    (1) the most common malignant (cancerous) brain tumor, accounting for
approximately \1/2\ of all primary malignant brain tumors; and

    (2) the most aggressive, complex, difficult to treat, and deadly type
of brain tumor;

Whereas it is estimated that more than 10,000 individuals in the United States
        will succumb to glioblastoma each year;
Whereas the 5-year survival rate for glioblastoma is only 7 percent, and the
        median survival rate following all diagnosed cases is only 8 months;
Whereas glioblastoma is described as a disease that affects the ``essence of
        self'', as the treatment and removal of glioblastoma presents
        significant challenges due to the uniquely complex and fragile nature of
        the brain, the primary organ in the human body that controls not only
        cognitive ability, but also the actions of every organ and limb;
Whereas patients and caregivers play a critical role in furthering research for
        glioblastoma;
Whereas, relative to patients with other types of cancers, brain cancer patients
        pay the second highest out-of-pocket costs for medical services in both
        the initial and end-of-life phases of care;
Whereas, although research advances may fuel the development of new treatments
        for glioblastoma, challenging obstacles to accelerating progress toward
        new treatments for glioblastoma remain, and there are no screening or
        early detection methods;
Whereas, in 2021, significant changes were made to the molecular characteristics
        of a glioblastoma diagnosis, necessitating critical biomarker testing
        for patients suspected of having a possible glioblastoma;
Whereas, although glioblastoma was first described in medical and scientific
        literature in the 1920s, and despite its devastating prognosis, only 5
        drugs and 1 medical device have been approved by the Food and Drug
        Administration to specifically treat glioblastoma since the 1920s, and
        the mortality rates associated with glioblastoma have changed little
        during the past 30 years;
Whereas, since the first Glioblastoma Awareness Day, the National Cancer
        Institute established the Glioblastoma Therapeutics Network (referred to
        in this preamble as ``GTN'') in 2020 as part of a national
        infrastructure to enhance and support the discovery and development of
        glioblastoma therapies available for multi-institutional GTN teams to
        drive therapeutic agents through preclinical studies and early phase
        clinical trials, which are necessary to rapidly evaluate potential
        treatments to advance toward cures and improved quality of life; and
Whereas there is a need for greater public awareness of glioblastoma, including
        awareness of both--

    (1) the urgent unmet medical needs of glioblastoma patients; and

    (2) the opportunities for research of, and treatment advances for,
glioblastoma: Now, therefore, be it

    Resolved, That the Senate--
            (1) designates July 15, 2026, as ``Glioblastoma Awareness
        Day'';
            (2) encourages increased public awareness of glioblastoma;
            (3) honors the individuals who have died from the
        devastating disease of glioblastoma or are currently living
        with the disease;
            (4) supports efforts to develop better treatments for
        glioblastoma that will improve the long-term prognosis for, and
        the quality of life of, individuals diagnosed with the disease;
            (5) recognizes the importance of molecular biomarker
        testing to the diagnosis and treatment of glioblastoma;
            (6) expresses support for the individuals who are battling
        brain tumors, as well as the families, friends, and caregivers
        of those individuals;
            (7) urges a collaborative approach to brain tumor research
        among governmental, private, and nonprofit organizations, which
        is a promising means of advancing the understanding and
        treatment of glioblastoma; and
            (8) encourages continued investments in glioblastoma
        research and treatments, including through the Glioblastoma
        Therapeutics Network and other existing brain tumor research
        resources.
                                 <all>